Reviews/Vitamin B12/Vitamin B12 corrects deficiency neuropathy
Neurocognition · VITB12-NEURO-01 · v2
The claim bundles two things: that a B12 deficiency actually causes nerve damage, and that fixing the deficiency reverses it. The corpus links low B12 to more neuropathy, both in people whose deficiency comes from metformin [2] and through a tissue-deficiency marker that tracks worsening nerve scores [15], but a link is not proof of cause. The evidence that B12 helps nerves comes almost entirely from patients with diabetic neuropathy [3][17], a condition with many causes, so it does not show that a deficiency alone drove the damage or that deficiency-caused nerve damage reverses. The one clean test that gave B12 to genuinely deficient older people and measured nerves objectively found no benefit [10]. No study here looks at the textbook case of B12-deficiency nerve damage being treated and recovering. The panel therefore landed on genuine uncertainty rather than confirming or rejecting the claim.
The corpus demonstrates an association between B12 deficiency and neuropathy: long-term metformin use raised biochemical B12 deficiency and "Neuropathy prevalence was higher in MET with low B12 levels" [2], and rising methylmalonic acid, a tissue-deficiency marker, tracked worsening of a validated neuropathy score [15]. It shows that B12 supplementation improved neurophysiological parameters, pain and quality-of-life measures in diabetic-neuropathy populations [3], and that parenteral B12 reduced pain and paresthesia scores in painful diabetic neuropathy [17]. Against reversibility, the one trial that supplemented genuinely (moderately) deficient older people and measured nerve conduction directly found no effect on the primary outcome (mean difference −0.2 mV; 95% CI −0.8, 0.3 mV) [10]. The corpus contains no study of classic B12-deficiency neuropathy repletion and recovery. The contested point: The division is whether the diabetic-neuropathy improvement seen in [3] and [17] speaks to the claim at all, given that deficiency is not established as the cause in those populations and B12 was given to patients with existing neuropathy rather than to deficiency-caused neuropathy. The clean deficiency-repletion trial [10] pulls the other way with a null objective result, but its enrolment of patients without neurologic signs limits how far it refutes reversal of symptomatic deficiency neuropathy.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin B12, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Nearly all positive signal is in DIABETIC neuropathy ([3],[17]), a multifactorial condition; improvement on B12 there does not show a deficiency caused a neuropathy, nor that deficiency neuropathy is reversible — population mismatch to the claim.
The causal conjunct rests on associations ([2],[15]) confounded by metformin exposure and glycaemia; association is not causation and reverse/confounded pathways are unaddressed.
Where it remains uncertain. The only clean deficiency-repletion trial with objective nerve conduction endpoints was null (mean difference −0.2 mV; 95% CI −0.8, 0.3 mV) [10], and no classic deficiency-neuropathy reversal study is present.
Aleatory
Reversibility signals come from modest randomized trials (N=90 [3], N=100 [17]) and the null repletion trial enrolled 201 with 191 providing outcome data [10], leaving room for chance in either direction.
Epistemic
No study of classic B12-deficiency neuropathy (pernicious anaemia, subacute combined degeneration) with repletion exists in the corpus, so the central case of the claim is simply untested here.
Inferential
Reversibility evidence is drawn from diabetic neuropathy [3][17], a multifactorial condition, and applying it to deficiency-caused neuropathy requires an inference the corpus does not support.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Association between B12 deficiency and neuropathy (causal conjunct), observational.
“Neuropathy prevalence was higher in MET with low B12 levels.”
Panel auditInternal validity: medium · scope of inference: Association between metformin-associated biochemical B12 deficiency and neuropathy prevalence in a diabetes-prevention population.Key limitations: observational for the neuropathy link · no reversibility tested · confounded by metformin and diabetes risk
Reversibility signal, but in diabetic (multifactorial) neuropathy.
“The treatment of patients with DN with 1 mg of oral methylcobalamin for twelve months increased plasma B12 levels and improved all neurophysiological parameters, sudomotor function, pain score, and QoL, but it did not improve CARTS and MNSIE.”
Panel auditInternal validity: high · scope of inference: Effect of correcting B12 (levels <400 pmol/L) on diabetic peripheral and autonomic neuropathy in type 2 diabetes on metformin.Key limitations: diabetic neuropathy, not isolated deficiency neuropathy · entry threshold <400 pmol/L not true deficiency · co-existing diabetic mechanism
Clean repletion RCT with objective nerve conduction endpoint — null; counters reversibility.
“there was no evidence of an effect of supplementation on the primary outcome of the posterior tibial compound muscle action potential amplitude at 12 mo (mean difference: -0.2 mV; 95% CI: -0.8, 0.3 mV)”
Panel auditInternal validity: high · scope of inference: Effect of B12 repletion on nerve and cognitive function in moderately deficient elderly without anemia or neurologic signs.Key limitations: participants had no neuropathy at baseline · moderate not severe deficiency · cannot test reversal of established neuropathy
3 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Association and confounded improvement signals are partly offset by a null clean-repletion trial and absent archetypal evidence, leaving the conjunct claim genuinely uncertain on this corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Classic deficiency-neuropathy repletion trial. The corpus has no study of pernicious anaemia or subacute combined degeneration treated with B12, which is the exact population the claim describes. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort or RCT enrolling patients with symptomatic B12-deficiency neuropathy, repleting B12, and following objective nerve conduction and clinical signs over 12 months.
Open question: Does repleting B12 reverse neuropathy in patients whose neuropathy arises from classic B12 deficiency? Why it is still open: No study of classic B12-deficiency neuropathy repletion exists in the corpus; reversibility evidence is confined to diabetic populations [3][17].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19